logo-loader
viewBirchBioMed Inc

Birch Biomed continues to head towards market with their unique products

"Birch BioMed’s co-founder Mark Miller spoke to Proactive Investors at the 11th Annual LD Micro Main Event in Los Angeles.

Spun off from the University of British Columbia, BirchBioMed is a private clinical-stage biomedical company that focuses on the development and production of anti-scarring drugs as well as autoimmune therapeutics and strategies for transplantation. Its lead drug candidate is FS2, which was first identified by investigators at UBC, and is able to target scarring at a molecular level. "
 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tabula launches new ETF focussing on North American High Yield Credit Market

Tabula Investment Management Limited (LSE: TABS) CEO MJ Lytle joined Steve Darling from Proactive with news the company has started a new ETF that will be exclusively located on the London Stock Exchange under the ticker “TABS”  Lytle telling Proactive that ETF will focus on short exposure...

17 hours, 49 minutes ago

2 min read